Imatinib Rowex

Imatinib, the active ingredient in Imatinib Rowex, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting specific cellular pathways that drive malignant growth.

GNH USA supplies Imatinib Rowex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring EU‑standard quality and reliable global distribution.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT, and PDGFR tyrosine kinase pathways. - Chronic myeloid leukemia (CML): achieves hematologic and cytogenetic remission by inhibiting BCR‑ABL kinase activity. - Gastrointestinal stromal tumor (GIST): reduces tumor progression by blocking c‑KIT and PDGFR signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides disease control through BCR‑ABL inhibition.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset that may improve with food. - Diarrhea: frequent loose stools, occasionally requiring hydration. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Hepatotoxicity: significant elevation of liver enzymes, jaundice, or liver failure requiring monitoring. - Myelosuppression: reduction in blood cell counts leading to neutropenia, anemia, or thrombocytopenia, increasing infection or bleeding risk. - Severe skin reactions: rare but life‑threatening conditions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, necessitating immediate medical attention.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety. - Baseline assessment: obtain complete blood count and liver function tests before initiating therapy. - Monitoring: perform regular CBC and hepatic panels during treatment to detect cytopenias or liver toxicity. - Cardiac evaluation: assess cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications for potential CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Imatinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce imatinib exposure, decreasing therapeutic effect.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption; separate dosing by at least 2 hours. - Anticoagulants (e.g., warfarin): imatinib may enhance anticoagulant effect, requiring INR monitoring. - Live attenuated vaccines: potential reduced efficacy; consider timing of vaccination.